A practical reference on pentadecapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-19. Anything still debated is marked as such rather than presented as settled.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Lyophilized powder storage | -20 C or colder, desiccated, protected from light | Long-term condition cited in supplier documentation |
| Reconstituted solution storage | 2-8 C for short-term use | Stability decreases after dissolution |
| Appearance | White to off-white lyophilized powder | Used as a visual identity check |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar organic solvents |
| Typical analytical method | Reversed-phase HPLC with UV detection at 214 nm | Purity estimate; mass spectrometry confirms molecular mass |
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
In July 2019, Feige announced the Phase Four (2021–2022) slate of films and series at San Diego Comic-Con (SDCC), including the animated series What If...? (2021–2024). By July 2021, the studio was creating an "animation branch and mini studio", known as Marvel Studios Animation, to focus on more animated content. Alonso said Marvel had around 31 projects in various stages of development by September 2021. In April 2022, Feige said he and Marvel Studios were on a creative retreat to plan and discuss the MCU films for the following 10 years. Following comments that there was no clear plan for the franchise in Phase Four compared to the Infinity Saga, Feige announced at SDCC in July 2022 that Phases Four, Five (2023–2025), and Six (2025–2027) would collectively be known as "The Multiverse Saga", and would culminate in the films Avengers: The Kang Dynasty and Avengers: Secret Wars (2027). Marvel Studios decided to not have an Avengers crossover film in each phase due to the large expansion in the number of MCU projects in a short amount of time, and after the "creative experience" of ending the Infinity Saga with Infinity War and Endgame. The studio was excited to explore Kang the Conqueror as an overarching villain of the Multiverse Saga after Thanos in the Infinity Saga, because Kang was a different villain in part due to his multiple alternate universe variants from different timelines within the multiverse.
because it is above thorium's 6.3 eV first ionization energy, neutral 229mTh can decay by internal conversion, and will almost always do so, rather than emitting a photon, and because it is above the 6.2 eV vacuum ultraviolet cutoff, the produced photons cannot travel through air. But even when experiments were redesigned to detect the higher energy, most of the searches in the 2010s for light emitted by the isomeric decay failed to observe any signal, pointing towards a potentially strong non-radiative decay channel. A direct detection of photons emitted in the isomeric decay was claimed in 2012 and again in 2018. However, both reports were controversial within the community. A direct detection of electrons being emitted in the internal conversion decay channel of 229mTh was achieved in 2016. However, at the time the isomer's transition energy could only be weakly constrained to between 6.3 and 18.3 eV. Finally, in 2019, non-optical electron spectroscopy of the internal conversion electrons emitted in the isomeric decay allowed for a determination of the isomer's excitation energy to 8.28±0.17 eV. However, this value appeared at odds with the 2018 preprint showing that a similar signal as an 8.4 eV xenon VUV photon can be shown, but with about 1.3+0.2−0.1 eV less energy and a (retrospectively correct) 1880±170 s lifetime. In that paper, 229Th was embedded in SiO2, possibly resulting in an energy shift and altered lifetime, although the states involved are primarily nuclear, shielding them from electronic interactions.
Protein phosphorylation, a post-translational modification, helps to regulate protein function and involves the phosphorylation of amino acids with hydroxyl groups in their side chains (among eukaryotes). Serine, threonine, and tyrosine amino acids are common targets of phosphorylation. Phosphorylation of Hsp70 has become a point of greater exploration in scientific literature relatively recently. A 2020 publication suggests that phosphorylation of a serine residue between the NBD and substrate binding domain in yeast Hsp70s leads to a dramatic reduction of the normal Hsp70 heat shock response. This deactivation via phosphorylation of a protein is a common motif in protein regulation, and demonstrates how relatively small changes to protein structure can have biologically significant effects on protein function.
===== Cetacean research ===== Peacock & Thewissen (2026) compare volume measurements of the bony labyrinth in extant mammals and Eocene cetaceans, and hypothesize that fossil cetaceans had membranous ducts of relatively larger size compared to terrestrial even-toed ungulates, and that vestibular organs of early cetaceans were necessary for terrestrial locomotion. Buono et al. (2026) reconstruct changes of cetacean morphological diversity and ecospace occupancy throughout the evolutionary history of the group, identifying Eocene–Oligocene and Plio–Pleistocene transitions as periods of major evolutionary changes, and linking changes of ecospace occupancy to the main radiation events of the group. Tyborowski et al. (2026) report the discovery of a portion of a dentary of an indeterminate member of Pelagiceti from the Siemień Formation, representing the first record of an Eocene whale from Poland and one of the smallest fully aquatic Eocene whales reported to date. A deciduous tooth of a basilosaurid with evidence of malformation that might have been caused by localized stress is described from the Eocene Submeseta Formation (Seymour Island, Antarctica) by Bajor et al. (2026). Hakkens, Reumer & Schulp (2026) study the affinities of the basilosaurid specimen TM 8501 from the Eocene (Priabonian) Yazoo Clay (Alabama, United States; the holotype of Zeuglodon hydrarchus), identify the studied individual as a mid-sized cetacean distinct from Dorudon serratus and Chrysocetus healyorum, an tentatively refer the specimen to Zygorhiza kochii. Davydenko et al.
Sources: en.wikipedia.org
There have been many walking courses over the years since, growing in participation at international locations. Mattie J.T. Stepanek (1990-2004), an American poet and peace activist, died aged 13 from dysautonomic mitochondrial myopathy, an inherited disease that causes muscle weakness and impairs heart rate, breathing, blood pressure, and digestion. Predeceased by his older siblings, he was survived by his mother (then aged 44), who was diagnosed in 1992 with a late-onset form of the same disease. Charles Darwin (1809-1882), an English naturalist and biologist, suffered from a chronic illness that has been speculated to have been MELAS syndrome (a mitochondrial myopathy).
== Economy == Major companies based in Yavne include Ormat Industries, Aeronautics Defense Systems, Avisar and Orbotech. In 2019, Merck established an incubator in Yavne with a budget of about €20 million over three years that will invest in startups focusing on semiconductor and display crystal technologies. In 2022 Recipharm established a new facility in Yavne. MediWound manufactures NexoBrid in Yavne, a unique product for the treatment of severe burns. It allows saving affected tissue which would otherwise need to be removed, leading to less amputations of hands and feet. Many October 7, 2023 victims have benefitted from it, with the US also buying $20 million worth of NexoBrid for its strategic national stockpile. In 2012 a new green neighborhood "Neot Rabin" was inaugurated in the south of the city.
=== In development === Several new drugs and treatments are under development for snakebite. For instance, the metal chelator dimercaprol has recently been shown to potently antagonize the activity of Zn2+-dependent snake venom metalloproteinases in vitro. New monoclonal antibodies, polymer gels and a small molecule inhibitor called Varespladib are in development. A core outcome set (minimal list of consensus outcomes that should be used in future intervention research) for snakebite in South Asia is being developed. In an article published in Nature in October 2025, a group led by researchers from the Technical University of Denmark has presented the possibility of a broad-spectrum antivenom that can work against the bites of many different snakes. They have developed an experimental polyvalent recombinant anti-venom that the authors claim to be capable of neutralising seven toxin families or subfamilies. A study conducted by Jacob Glanville used two antibodies taken from the memory B cells of blood from a "hyperimmune" donor, who had been deliberately bitten by many species of snake, to develop an antivenom "cocktail". Elapidae were the focus of the study, of which nineteen are classified as being the deadliest on Earth by the World Health Organization. Tested on mice, the antivenom cocktail prevented death from thirteen of the nineteen species, with partial protection observed from the other six.
Sources: en.wikipedia.org
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.
Low temperature and low moisture slow hydrolysis and oxidation, the two main degradation routes for short peptides. A desiccant limits water uptake each time the vial is opened.
No single number captures identity, counter-ion content, water content, or sterility. A purity figure from one laboratory method reflects only what that method detects, and different methods can give different values for the same sample.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.